Introducing OncoK9™, a pioneering blood-based multicancer early detection (MCED) test for dogs
According to the National Cancer Institute, approximately 6 million new cancer diagnoses are made in dogs each year. Like humans, dogs have a 1 in 3 lifetime risk of getting cancer, Older dogs, and certain predisposed breeds, are at higher risk of developing cancer. Cancer is typically diagnosed in dogs at an advanced stage, when treatment options are limited, and chances of a cure are low. Each year, cancer cuts short the lives of many dogs who might have enjoyed many healthy years with their families had the disease been detected earlier.
OncoK9 OncoK9 Intended Use OncoK9 is a multi-cancer early detection (MCED) test for the detection and characterization of cancer-associated genomic alterations in DNA isolated from canine whole blood samples, using next-generation sequencing (NGS) technology. OncoK9 is intended for use in dogs who are at higher risk of cancer. It is recommended as an annual screening test for all dogs starting at 8 years of age and potentially at younger ages for dogs belonging to breeds that are highly predisposed to cancer. It is also recommended as an aid-in-diagnosis for dogs in which cancer is suspected based on clinical signs or other clinical findings. As with any laboratory test, OncoK9 results should be interpreted by a veterinarian in the context of each patient’s medical history and clinical presentation. The test is available by prescription only. Please consult with your veterinarian as he/she has to order for your precious pup. For Additional Information please visit https://petdx.com.